Oncternal Completes Enrollment And Dosing Initiated For 5th Dose Cohort Of Phase 1/2 Study Of ONCT-534 For The Treatment Of R/R Metastatic Castration-Resistant Prostate Cancer
Portfolio Pulse from Benzinga Newsdesk
Oncternal Therapeutics, Inc. (NASDAQ:ONCT) has completed enrollment and initiated dosing for the fifth dose cohort in its Phase 1/2 study of ONCT-534 for treating metastatic castration-resistant prostate cancer. The Safety Review Committee approved the 600 mg dose after reviewing data from the 300 mg dose. Initial safety and efficacy data are expected in Q3 2024.
May 30, 2024 | 8:45 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Oncternal Therapeutics has completed enrollment and initiated dosing for the fifth dose cohort in its Phase 1/2 study of ONCT-534 for metastatic castration-resistant prostate cancer. Initial safety and efficacy data are expected in Q3 2024.
The completion of enrollment and initiation of dosing for the fifth cohort in the Phase 1/2 study of ONCT-534 is a significant milestone for Oncternal Therapeutics. This progress indicates that the study is advancing as planned, which is positive news for the company. The anticipation of initial safety and efficacy data in Q3 2024 could generate investor interest and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100